The increased incidence of autoantibodies in malignancies has been described since the 1970s. Thus the ability to determine molecular fingerprinting of autoantibodies (antibody signatures) may provide useful clinical diagnostic and prognostic information. This review describes the use of several proteomics approaches for the identification of antigens recognized by these autoantibodies. Serological proteome analysis combines separation of tumor cell proteins on two-dimensional gel electrophoresis gels, Western blotting with sera of patients and healthy subjects, and identification of the detected antigens by MS. Alternatively multiple affinity protein profiling combines isolation of the antigens recognized by patient antibodies by two-dimensional immunoaffinity chromatography and identification by MS/ MS. The use and limitations of reverse phase protein microarrays for testing patient serum containing autoantibodies are also considered. Lastly the most important difficulty of any proteomically identified autoantibody signature is validation in patient cohorts or clinical samples. © 2007 by The American Society for Biochemistry and Molecular Biology, Inc.
CITATION STYLE
Caron, M., Choquet-Kastylevsky, G., & Joubert-Caron, R. (2007, July). Cancer immunomics using autoantibody signatures for biomarker discovery. Molecular and Cellular Proteomics. https://doi.org/10.1074/mcp.R600016-MCP200
Mendeley helps you to discover research relevant for your work.